Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for Inflammatory Storm in COVID-19
NCT04647604Phase 2Completed
- Sponsor
- Karolinska University Hospital
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid + docosahexaenoic acid in coronavirus disease 2019 (COVID-19), sponsored by Karolinska University Hospital. Started Jun 2020; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04647604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647604.